Quintiles has celebrated the 30th anniversary of its foundation by highlighting some of its achievements over the last three decades.
The biopharmaceutical services provider was established on February 26th 1982 and has since grown into one of the largest organisations of its kind in the world, with more than 25,000 employees and offices in over 60 nations.
All 50 of the world's top-selling pharmaceutical products in 2010 were created using development or commercialisation support from Quintiles, a claim the company has been able to make for at least a decade.
Quintiles chairman and chief executive officer Dr Dennis Gillings noted that the organisation remains actively involved in the development of therapies for conditions such as Alzheimer's, cancer, diabetes, heart disease and infectious disease.
He added: "Even in the earliest days, we recognised that Quintiles could make a difference in people's lives. Today, millions, if not billions of people have been impacted by our work."
Over the last few months, the company has announced several plans to expand further, establishing new commercial services in the Middle East and north Africa, as well as a biomarker-focused research and development business.